Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343224 · ClinicalTrials.gov registry record · Phase 2
Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02343224 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 9 participants.
The verdict
NCT02343224, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a phase II study of the drug, pegylated interferon alfa-2b (PEG-Intron), used to treat brain tumors in a pediatric population. Researchers want to see if treatment with PEG-Intron will stop tumor growth for patients with juvenile pilocytic astrocytomas or optic pathway gliomas. The purposes of this study are: * To learn more about the response to pegylated interferon * To learn more about the side effects of pegylated interferon * To learn more about MRI images in patients with Juvenile Pilocytic Astrocytomas or Optic Pathway Gliomas. * To learn more about quality of life in patients treated with pegylated interferon
Interventions
- DRUG Pegylated interferon alpha-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-11 |
| Est. Completion | 2020-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02343224
The ClinicalTrials.gov registry entry for NCT02343224 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegylated interferon alpha-2b is the first listed.
NCT02343224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02343224 about?
NCT02343224 is a clinical study titled "Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas". This is a phase II study of the drug, pegylated interferon alfa-2b (PEG-Intron), used to treat brain tumors in a pediatric population. Researchers want to see if treatment with PEG-Intron will stop tumor growth for patients with juvenile pilocytic astrocytomas or optic pathway gliomas. The purposes...
What is the current status of trial NCT02343224?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2014-11. Estimated completion is 2020-11-11.
What interventions are being tested in trial NCT02343224?
The interventions under investigation include: Pegylated interferon alpha-2b (DRUG).
Who is sponsoring clinical trial NCT02343224?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.